Ibogaine Treatment Centers: A Clinician’s Guide to How Ibogaine Therapy Works, What to Expect at a Treatment Center, the Safety Concerns, and the Evidence Base for Treating Opioid and Other Substance Use Disorders

What ibogaine is, how the substance acts on the brain to interrupt addiction, what the typical experience at a licensed ibogaine treatment center looks like from medical screening through dosing to integration, the cardiac and other safety concerns that make rigorous medical supervision essential, the current evidence base for ibogaine in opioid use disorder, and how to evaluate whether a particular treatment center meets reasonable safety standards.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

Ibogaine is a naturally occurring alkaloid found in the root bark of the Tabernanthe iboga plant native to West Africa, which has gained substantial attention in the past two decades as a potential treatment for opioid use disorder, alcohol use disorder, and other forms of addiction. Ibogaine treatment centers are facilities that offer structured ibogaine therapy in countries where the substance is legal or unregulated, including Mexico, Costa Rica, Brazil, Canada, New Zealand, South Africa, and several others. The substance is Schedule I in the United States, where it cannot be legally administered outside of FDA-approved research, which has driven the growth of treatment centers in other jurisdictions. The typical treatment protocol involves comprehensive medical screening including cardiac evaluation, a single high dose of ibogaine administered in a medical setting with continuous cardiac monitoring, a 24 to 36 hour intense experience followed by 1 to 2 weeks of recovery and integration, and aftercare planning for the months after treatment. Patient reports often describe a substantial reduction in opioid craving and withdrawal symptoms following treatment. The evidence base is growing but remains limited compared with FDA-approved medications, and the substance carries meaningful cardiac risk including QT prolongation that has been associated with deaths in inadequately screened patients. Selecting a reputable treatment center with proper medical infrastructure, qualified physicians, and rigorous screening protocols is essential.

What ibogaine is and where it comes from

Ibogaine is the principal psychoactive alkaloid found in the root bark of Tabernanthe iboga, a shrub native to the rainforests of West and Central Africa, particularly Gabon, Cameroon, and the Republic of the Congo. The plant has been used for centuries in the Bwiti spiritual tradition of the Fang and Mitsogo peoples of Gabon, where it is taken in ceremonial initiation rites that involve large doses producing a multi-day visionary experience. The Western pharmacological investigation of ibogaine began in the early 20th century with French researchers identifying the alkaloid in the 1900s, and the substance was used briefly in France as a stimulant and antidepressant under the brand name Lambarene in the 1930s before being withdrawn from the market.

The modern interest in ibogaine as a treatment for addiction is generally traced to the work of Howard Lotsof, a young heroin user in New York who tried ibogaine in 1962 and reported that the experience eliminated his heroin craving and withdrawal symptoms. Lotsof spent decades attempting to bring ibogaine into formal medical use in the United States, securing patents for ibogaine treatment of opioid use disorder and other addictions, but encountering substantial regulatory barriers. The U.S. Drug Enforcement Administration placed ibogaine in Schedule I in 1970 alongside other hallucinogens, making research and clinical use difficult in the United States. Research and clinical practice has consequently developed primarily in other jurisdictions.

The chemistry of ibogaine and its metabolite noribogaine produces a complex pharmacological profile that does not fit neatly into any single drug class. Ibogaine acts at multiple receptor systems including the NMDA glutamate receptor, the sigma receptors, the kappa-opioid receptor, the serotonin transporter, and the alpha-3-beta-4 nicotinic acetylcholine receptor. The action at the nicotinic receptor is thought to be particularly important for the anti-addictive effects, as this receptor is involved in the reinforcement of multiple substances including nicotine, opioids, stimulants, and alcohol. The substance also acts as a hallucinogen at high doses, producing visionary experiences that are characteristic of the ceremonial Bwiti use and that occur during high-dose treatment in modern ibogaine centers.

How ibogaine treatment is thought to work

The mechanism by which ibogaine produces its claimed anti-addictive effects is not fully understood and is the subject of ongoing research. Several mechanisms have been proposed and likely contribute to the overall clinical effect. The action at the alpha-3-beta-4 nicotinic acetylcholine receptor appears to reduce the reinforcing effects of multiple substances of abuse, possibly by interrupting the dopaminergic signalling that maintains the addictive cycle. This receptor effect would explain the substance’s apparent effectiveness across multiple substance types rather than being specific to opioids.

The metabolism of ibogaine in the liver produces noribogaine, which has its own pharmacological profile distinct from ibogaine and which persists in the body for days to weeks after the original dose. Noribogaine appears to occupy mu-opioid and kappa-opioid receptors as a partial agonist, which may contribute to the suppression of opioid withdrawal during and after the ibogaine experience. The sustained presence of noribogaine may also explain the relatively long window of reduced craving that patients describe after treatment.

The visionary experience that high-dose ibogaine produces is thought to contribute therapeutically through psychological mechanisms similar to those proposed for psilocybin-assisted therapy and other psychedelic treatments. Patients report intense visions, life review, contact with what feels like a higher intelligence, and profound insights into the origins and patterns of their substance use. The reframing of the addiction in the context of the visionary experience may produce durable cognitive and motivational changes that support recovery in the months after treatment. The relative contributions of the receptor-level effects and the psychological effects are not separable in the current treatment paradigm and may both matter for outcomes.

The substance does not appear to produce dependence or compulsive use itself. The intense, prolonged, and often physically uncomfortable nature of the high-dose ibogaine experience means that repeated dosing within short intervals is not sought even by users who found the experience valuable. Most ibogaine treatment protocols involve a single high-dose session, sometimes followed by booster doses at lower levels over the following weeks, but the substance does not produce the daily use patterns characteristic of opioids, stimulants, alcohol, or benzodiazepines.

What happens at an ibogaine treatment center

A typical treatment program at a reputable ibogaine treatment center spans 7 to 14 days and includes several distinct phases. The pre-treatment phase begins with extensive medical and psychiatric screening, often conducted over several weeks before arrival at the center. The screening includes detailed substance use history, medical history with particular attention to cardiac history, family history of heart disease or sudden death, psychiatric history including any psychotic illness or bipolar disorder which are typically contraindications to treatment, current medications, blood tests including liver function, kidney function, electrolytes, and a complete blood count, and a 12-lead electrocardiogram with measurement of the QT interval.

Patients with opioid use disorder are typically transitioned from short-acting opioids onto a more stable opioid such as morphine before treatment, then allowed to enter mild withdrawal before the ibogaine dose is given. Patients on methadone require longer preparation because of methadone’s long half-life and the importance of having low methadone blood levels before ibogaine administration. Patients on buprenorphine usually need transition to a short-acting opioid for several days before treatment because of buprenorphine’s high mu-opioid receptor affinity. These preparation steps require medical management and are part of the reason that treatment in a structured center is safer than self-administration.

The arrival at the center includes additional in-person medical evaluation, repeat ECG, and final review of suitability for treatment. Many centers conduct a test dose of ibogaine the day before the main treatment to assess individual sensitivity and to check for any unexpected adverse responses. The accommodation is usually private or semi-private, with a comfortable bed and quiet environment for the dosing day and the recovery period. Reputable centers have on-site or rapidly accessible emergency medical care and cardiac monitoring equipment.

The main treatment day begins with the administration of the full ibogaine dose, typically 12 to 20 milligrams per kilogram of body weight, given orally as capsules over a period of one to two hours. Cardiac monitoring is continuous throughout the experience using telemetry equipment that tracks heart rate, rhythm, and QT interval. Vital signs including blood pressure, oxygen saturation, and temperature are checked regularly. A trained physician is present in the facility throughout the experience and is available for any acute medical concerns. The acute experience lasts approximately 24 to 36 hours, with the most intense visionary phase typically beginning 1 to 2 hours after dosing and continuing for 6 to 12 hours.

The ibogaine experience: what patients describe

Patient accounts of the ibogaine experience are notably consistent across treatment centers and across substance use disorders. The acute phase begins with physical sensations including muscle weakness, ataxia, nausea, and a sense of the body becoming progressively heavier and less responsive. Patients typically lie in bed throughout the experience as standing and walking become difficult and increase the risk of falls. The visual phenomena begin as the dose takes full effect, often described as scenes from the patient’s past appearing in front of closed eyes with a film-like quality, accompanied by emotional content that the patient can observe rather than being immersed in.

The middle phase is often described as a life review or as scenes from the patient’s substance use history presented from an outside perspective. Patients describe seeing themselves at various ages, witnessing events they had forgotten or had not consciously processed, and gaining what feels like an objective understanding of how their substance use developed and what purpose it served. The emotional quality of this phase is often described as compassionate and curious rather than judgmental, with patients reporting a sense of acceptance and understanding rather than shame or guilt.

The late phase is often described as a return to baseline alertness with persistent insights, accompanied by physical fatigue and continuing mild perceptual changes. The full return to ordinary consciousness typically occurs 24 to 36 hours after dosing. Patients describe feeling physically depleted, emotionally raw but generally peaceful, and clear-headed in a way that is different from their ordinary baseline. Opioid users typically report substantial reduction or absence of the withdrawal symptoms that would otherwise be peaking at this point in their detoxification. Some patients describe immediate elimination of craving for their drug of choice, while others describe a quieter relationship with the craving that allows them to engage with it without acting on it.

The 1 to 2 weeks following the acute experience involve continued residence at the treatment center for medical monitoring, processing of the experience with center staff, and beginning of integration work. Sleep is often disturbed in the first week. Appetite gradually returns. Energy slowly rebuilds. Many patients describe a window of clarity in the weeks after treatment in which decisions about life direction, relationships, and recovery activities feel easier to make than they did before the treatment. This window is typically used productively for integration work and for planning the aftercare that will support long-term recovery.

Safety concerns and the cardiac risk

The most clinically important safety concern with ibogaine is cardiac. The substance prolongs the QT interval on the electrocardiogram, a marker of delayed ventricular repolarisation that can predispose to potentially fatal arrhythmias including torsades de pointes. The risk is dose-related and is particularly elevated in patients with pre-existing long QT, electrolyte disturbances including low potassium or magnesium, use of other QT-prolonging medications, and underlying structural heart disease. Multiple deaths have been reported from cardiac arrhythmias during ibogaine treatment, both in formal treatment center settings and in informal self-administration.

The standard safety protocol in modern ibogaine treatment centers includes baseline ECG with QT measurement, exclusion of patients with QTc greater than 450 milliseconds, correction of any electrolyte abnormalities before treatment, screening for medications that prolong QT including some antibiotics, antifungals, antidepressants, and antiarrhythmics, and continuous cardiac monitoring during the acute experience with intervention available if dangerous rhythm changes develop. Centers that follow these protocols rigorously have substantially reduced the cardiac mortality rate compared with earlier and less structured treatment, but the risk is not zero even with optimal screening and monitoring.

Other safety concerns include ataxia and risk of falls during the acute experience, which is mitigated by ensuring patients remain in bed throughout. Nausea and vomiting are common and require attention to airway protection. Psychiatric decompensation can occur in patients with vulnerability to psychotic illness, which is why patients with personal or family history of schizophrenia or bipolar disorder are typically excluded. The intense psychological content of the experience can be difficult or destabilising even for patients without psychiatric history, and adequate preparation and integration support are essential.

Drug interactions are clinically important. Patients on opioids, particularly methadone or buprenorphine, need careful management of the transition before ibogaine treatment because of the interactions at opioid receptors. Patients on antidepressants need attention to serotonin interactions. Patients on cardiac medications need particular care because of the QT prolongation concern. Reputable centers have physicians who manage these transitions, often beginning weeks before arrival at the center.

The evidence base for ibogaine in opioid use disorder

The current evidence base for ibogaine in opioid use disorder consists primarily of observational studies, case series, and patient self-report rather than the randomised controlled trials that establish standard medications. The available evidence is consistent in suggesting that a substantial proportion of patients experience meaningful reductions in opioid use and craving after ibogaine treatment, with effects persisting for weeks to months in many patients. Long-term outcomes including sustained abstinence over years are less well-documented, with some patients maintaining recovery for years and others returning to use within months.

A 2018 observational study by Brown and Alper of 30 patients with opioid use disorder treated with ibogaine in Mexico found that 12 of 30 patients had sustained reduction in opioid use at 12 months, with substantial overall improvements in mood and craving measures. A 2018 study by Davis and colleagues in New Zealand of 14 patients similarly showed sustained reductions in opioid use over 12 months. These observational studies have limitations including absence of control groups, selected patient populations who were motivated to seek treatment, and outcome measures that depend on patient self-report. The findings are encouraging but cannot be considered definitive.

Several clinical trials of ibogaine for opioid use disorder have been initiated in recent years in countries where the substance is legal for research. Trials in New Zealand, Brazil, and several other jurisdictions are in various stages of completion. A phase 2 trial sponsored by the company DemeRx is investigating noribogaine specifically. The MAPS organisation and several other research groups have advocated for FDA-approved research in the United States, with some progress in recent years but no approved clinical trials at the date of writing.

The evidence base for ibogaine in alcohol use disorder, stimulant use disorder, and other substance use disorders is less developed than for opioid use disorder. Case reports and observational studies suggest possible benefit but are not yet sufficient to support firm conclusions. The substance’s mechanism through the nicotinic receptor would in principle apply across multiple substance types, and clinical reports describe similar experiences and outcomes regardless of the primary substance of use. More rigorous research is needed across all the substance use disorders.

Choosing a reputable ibogaine treatment center

The differences between ibogaine treatment centers are substantial and the selection of a reputable center is one of the most important decisions a prospective patient can make. Several specific criteria distinguish reputable centers from less safe alternatives. The presence of a licensed physician on staff who is qualified to manage acute medical complications is essential. The use of continuous cardiac monitoring during the acute experience is essential. Comprehensive pre-treatment screening including ECG, blood tests, and detailed medical history is essential. On-site or rapidly accessible emergency medical capability is essential.

The location of the center matters for several reasons including the legal status of ibogaine in the host country, the quality of the local healthcare system in case of medical emergency, and the regulatory oversight to which the center is subject. Mexico has many ibogaine centers ranging from highly professional to dangerously informal, and the regulatory environment provides limited protection against substandard operators. Costa Rica has a smaller number of centers operating under varying levels of professionalism. New Zealand and Canada have more rigorous regulatory environments and have produced some of the more professional treatment centers but at higher cost. South Africa, the Czech Republic, and several other jurisdictions have emerging centers of varying quality.

The training and credentials of the staff matter substantially. Reputable centers employ physicians with addiction medicine training, nurses with experience in acute medical care, and integration specialists with mental health training. Less reputable centers may rely on lay practitioners with limited formal medical training, which substantially increases the risk profile. Prospective patients should ask specifically about the medical credentials of the team, the protocols for medical emergencies, and the relationships with local emergency medical services.

Aftercare planning is a feature of reputable centers and is essential for long-term outcomes. The acute ibogaine experience produces a window of opportunity for recovery but does not by itself produce sustained recovery in most patients. Aftercare typically includes integration sessions with center staff, connection with outpatient mental health and addiction medicine providers, structured planning for the first weeks and months after returning home, and ongoing contact with the treatment center for support. Centers that send patients home after the acute treatment without aftercare planning typically have substantially worse long-term outcomes.

How ibogaine treatment compares with FDA-approved options

Patients considering ibogaine treatment for opioid use disorder are typically also considering or have already tried the FDA-approved treatments including buprenorphine (Suboxone, Subutex, Sublocade), methadone, and extended-release naltrexone (Vivitrol). The comparison between ibogaine and these treatments is complex and involves trade-offs that depend on individual circumstances.

The FDA-approved medications have substantially stronger evidence bases, are widely available in the United States and other Western countries, are typically covered by insurance, can be used long-term safely, and produce well-characterised outcomes. The medications work primarily by occupying opioid receptors and preventing the rewarding effects of additional opioid use, with daily or monthly dosing. The trade-off is that the medications need to be continued for sustained benefit, with discontinuation associated with high relapse rates. Patients on buprenorphine or methadone for years describe stable function but are not in the same psychological state as patients who have undergone the more transformative ibogaine experience.

Ibogaine treatment in contrast is a one-time or occasional intervention that aims to interrupt the addictive cycle and reset the underlying motivation. When successful, the treatment can produce sustained recovery without ongoing medication. The trade-offs are the limited evidence base, the cardiac risk, the cost (typically $5,000 to $20,000 for a treatment program), the need to travel to a treatment center outside the United States, and the variable quality of available centers. Some patients combine the approaches, using ibogaine to interrupt the cycle and then transitioning to maintenance buprenorphine or naltrexone to support long-term recovery.

The choice between approaches depends on patient preference, severity of disorder, available resources, willingness to undertake the cardiac risk of ibogaine, and the patient’s response to previous treatments. Patients who have done well on buprenorphine may have no reason to consider ibogaine. Patients who have failed multiple courses of standard treatment may have stronger reason to consider an alternative approach. Patients with significant cardiac risk factors should generally avoid ibogaine regardless of other factors. The decision should be made with input from clinicians familiar with both approaches.

When alcohol use disorder is the primary concern

Alcohol use disorder, which is the clinical term for what most people call alcoholism, is also treated at some ibogaine treatment centers, though the evidence base is less developed than for opioid use disorder. The proposed mechanism through the nicotinic receptor would apply to alcohol as well as to opioids, and patient reports suggest some benefit. The medical safety considerations are similar to opioid use disorder treatment, with attention to the cardiac risk being central.

FDA-approved treatments for alcohol use disorder including naltrexone (oral or extended-release Vivitrol), acamprosate, and disulfiram have strong evidence bases and should typically be tried before considering ibogaine. Behavioural treatment with cognitive behavioural therapy, motivational enhancement therapy, and 12-step facilitation also has strong evidence. Phuket Island Rehab provides residential addiction medicine treatment for alcohol use disorder using these evidence-based approaches, with integrated mental health care and structured aftercare planning.

Practical considerations for prospective patients

Patients considering ibogaine treatment should approach the decision systematically. The first step is obtaining a comprehensive medical and psychiatric evaluation from a physician familiar with ibogaine, including cardiac assessment with ECG and review of any QT-prolonging medications. The second step is detailed research into available treatment centers, with attention to medical credentials, safety protocols, treatment outcomes, and aftercare planning. Verifying the credentials of physicians and the regulatory status of the facility is essential and is sometimes neglected.

Financial planning is important. Most ibogaine treatment is not covered by insurance and the out-of-pocket cost is substantial. The treatment cost is typically $5,000 to $20,000 depending on the location, the length of the program, and the level of service. Additional costs include travel to the center, time away from work, and aftercare services that may also not be covered. Patients should plan for the total cost rather than just the basic treatment fee.

Preparation for treatment is more involved than for most medical procedures. Pre-treatment requirements often include transitioning from current medications to those compatible with ibogaine, completing additional medical tests, and engaging with the center’s preparation materials including psychological preparation for the experience. The preparation typically begins several weeks before arrival at the center and continues through the first day at the facility.

Post-treatment planning is essential and should be in place before the treatment begins. Patients typically benefit from a structured aftercare plan that includes residence in a safe environment for the first weeks after treatment, ongoing connection with mental health and addiction medicine providers, support group attendance, and a clear plan for re-engagement with daily life. Patients who return immediately to the environment that supported their substance use typically have worse outcomes than those who can spend several weeks or months in a supportive transitional environment.

Summary

Ibogaine is a naturally occurring alkaloid that has shown promise as a treatment for opioid use disorder and other addictions, with treatment available at centers in countries where the substance is legal or unregulated. The typical treatment involves comprehensive medical screening, a single high dose given in a medical setting with continuous cardiac monitoring, a 24 to 36 hour intense experience, and 1 to 2 weeks of recovery and integration. Patient reports often describe substantial reductions in craving and withdrawal symptoms following treatment. The substance carries meaningful cardiac risk including QT prolongation that has been associated with deaths in inadequately screened patients, making selection of a reputable treatment center with proper medical infrastructure essential. The evidence base is growing but remains limited compared with FDA-approved treatments including buprenorphine, methadone, and naltrexone, which should typically be considered first. As Dr. Ponlawat Pitsuwan summarises, “Ibogaine treatment is one of the more interesting developments in addiction medicine outside the FDA-approved options. The evidence is encouraging but not yet definitive, the safety profile is real and requires rigorous medical infrastructure, and the choice between ibogaine and standard treatment depends on individual circumstances. For patients considering ibogaine, selecting a reputable treatment center with proper medical capability is the most important decision they will make in the process.”

Frequently asked questions

What is ibogaine treatment?

Ibogaine treatment is the medical use of ibogaine, an alkaloid from the Tabernanthe iboga plant, to interrupt addictive patterns particularly in opioid use disorder. The standard protocol involves comprehensive medical screening, a single high dose given in a medical setting with continuous cardiac monitoring, a 24 to 36 hour intense experience, and 1 to 2 weeks of recovery and integration. Treatment is available at centers in countries where ibogaine is legal or unregulated.

Is ibogaine legal?

Ibogaine is Schedule I in the United States, meaning it cannot be legally prescribed or used outside of FDA-approved research. The substance is legal or unregulated in many other countries including Mexico, Costa Rica, Brazil, Canada (for clinical use), New Zealand, South Africa, the Czech Republic, and several others. Treatment centers operate in these countries to serve patients who cannot access ibogaine treatment legally in their home countries.

How much does ibogaine treatment cost?

The cost of a typical ibogaine treatment program ranges from approximately $5,000 to $20,000 depending on the location, the length of the program, and the level of service provided. The treatment is generally not covered by health insurance in the United States. Additional costs include travel to the treatment center, time away from work, and aftercare services that may also be uncovered.

Is ibogaine treatment dangerous?

Ibogaine carries meaningful medical risk, primarily cardiac. The substance prolongs the QT interval on the electrocardiogram and can precipitate potentially fatal arrhythmias including torsades de pointes. Multiple deaths have been reported, particularly in patients with pre-existing cardiac risk factors who were not adequately screened. The risk is substantially reduced but not eliminated by rigorous pre-treatment screening and continuous cardiac monitoring during the experience. Selecting a treatment center with proper medical infrastructure is essential.

Does ibogaine cure addiction?

Ibogaine does not cure addiction, but it can produce a window of substantially reduced craving and withdrawal that supports recovery if used as part of a comprehensive treatment approach. Long-term sustained recovery requires aftercare planning, ongoing psychological and behavioural treatment, and often medication-assisted treatment with FDA-approved medications. Patients who undergo ibogaine treatment without aftercare typically have worse outcomes than those with structured follow-up support.

How long does the ibogaine experience last?

The acute ibogaine experience typically lasts 24 to 36 hours from the initial dose to full return to baseline alertness. The most intense visionary phase usually begins 1 to 2 hours after dosing and continues for 6 to 12 hours. Physical recovery including normal sleep, appetite, and energy typically takes 1 to 2 weeks. Reduced craving and improved mood often persist for weeks to months after the acute experience.

Sources

• Alper KR, Lotsof HS, Frenken GMN, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions. 1999;8(3):234-242.
• Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse. 2018;44(1):24-36. https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1320802
• Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. Journal of Psychedelic Studies. 2017;1(2):65-73.
• Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Frontiers in Pharmacology. 2018;9:529. https://www.frontiersin.org/articles/10.3389/fphar.2018.00529/full
• National Institute on Drug Abuse (NIDA). Hallucinogens. https://nida.nih.gov/research-topics/hallucinogens
• Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences. 2012;57(2):398-412. https://onlinelibrary.wiley.com/doi/10.1111/j.1556-4029.2011.02008.x
• Substance Abuse and Mental Health Services Administration (SAMHSA). National Helpline. https://www.samhsa.gov/find-help/national-helpline

Ibogaine, noribogaine, Tabernanthe iboga, iboga, Bwiti, Gabon, Howard Lotsof, MAPS, DemeRx, Schedule I controlled substance, DEA, FDA, hallucinogen, psychedelic, alkaloid, partial agonist, NMDA glutamate receptor, sigma receptor, kappa-opioid receptor, mu-opioid receptor, alpha-3-beta-4 nicotinic acetylcholine receptor, serotonin transporter, dopamine, mesolimbic pathway, brain reward circuit, addiction medicine, opioid use disorder, OUD, alcohol use disorder, AUD, stimulant use disorder, nicotine use disorder, heroin, oxycodone, hydrocodone, methadone, buprenorphine, Suboxone, Subutex, Sublocade, naltrexone, Vivitrol, acamprosate, disulfiram, fentanyl, opioid withdrawal, Clinical Opiate Withdrawal Scale, COWS, ibogaine treatment center, Mexico, Costa Rica, Brazil, Canada, New Zealand, South Africa, Czech Republic, ECG, electrocardiogram, QT prolongation, QTc, torsades de pointes, ventricular arrhythmia, cardiac risk, sudden cardiac death, hepatotoxicity, ataxia, hallucinations, visionary experience, integration, aftercare, residential treatment, cognitive behavioural therapy, CBT, 12-step program, NIDA, SAMHSA, NHS, Phuket Island Rehab.